Overview

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study aims to establish the safety and toxicity of a combined intravesical mitomycin C with BCG for patients with bladder cancer.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Treatments:
BCG Vaccine
Mitomycin
Mitomycins